ERBB2 and neoplasm: Puttemans et al reported higher tumor accumulation for the HER2-targeted nanobody [111In]-2Rs15d (1h p.i.)compared to [111I]-Trastuzumab (3d p.i.)administered in a mouse model bearing intracranial SK-OV-3 tumors, suggested to have less disrupted BBB.